This fund has been developed in response to patients who have contacted PAF for help with their medication expenses and could not find help. While this fund has been fully designed and we are ready to provide needed support to these patient communities, this fund is not yet able to accept applications for assistance as we are still working to secure charitable donations that will allow us to open it.
If you, or someone you know, would like to contribute to this fund, please visit our Donors page for more information on how to provide critical support for patients in need.Fund Type
Co-pay, Co-Insurance & DeductibleMaximum Award Level
$8,000 Per Year
- Household Income Requirements 400% or less of Federal Poverty Guideline (FPG) (adjusted for Cost of Living Index (COLI) and number in household)
- Insurance Requirements Patient must be insured and insurance must cover the medication for which patient seeks assistance.
- Must reside and receive treatment in the United States.
Amyloidosis is a bone marrow disorder that produces an abnormal protein, called amyloid, that is then deposited in various organs and tissues of the body. Amyloidosis may be either primary (with no known cause), secondary (caused by another disease), or hereditary (passed down from parents to children). Localized amyloidosis may only affect a single tissue of the body, while systemic amyloidosis deposits may be found throughout the body, but most commonly affects the heart, liver, kidneys, spleen, nervous system or digestive tract; without treatment it can cause organ failure or death. The disease is typically diagnosed over the age of 40, and about two-thirds of patients are male.
Light chain amyloidosis (AL), is a disorder of the plasma cell, and is the most common form of Amyloidosis. Autoimmune amyloidosis (AA) occurs as a reaction to another chronic illness and is referred to as secondary or inflammatory amyloidosis. Hereditary or familial amyloidosis is rare, and is caused by inheriting a gene mutation; normally the harmful deposits don’t occur until adulthood. There are 2 classifications of hereditary amyloidosis which is considered a systemic disease, ATTR (transthyretin protein (TTR)), and Non-TTR. Leukocyte chemotactic factor 2 (LECT2), involves an amyloid subunit protein and is referred to as ALECT2. This disease is classified as an acquired systemic amyloidosis. At this time, the protein is thought to be part of cartilage reconstruction and tissue repair. Beta-2 microglobulin amyloidosis (AB2M) is associated with the B2M protein, and occurs with end stage renal (kidney) disease, resulting in the accumulation and deposit of this amyloid protein in bones, joints and tendons.
- Good Days877-968-7233
- Healthwell Foundation800-675-8416
- Leukemia & Lymphoma Society800-955-4572
- National Organization for Rare Disorders800-999-6673
- Needy Meds800-503-6897
- Patient Access Network Foundation866-316-7263
- Patient Services Inc.800-366-7741
- The Assistance Fund855-845-3663